...
首页> 外文期刊>Journal of biological inorganic chemistry: JBIC: a publication of the Society of Biological Inorganic Chemistry >Interactions of the the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease
【24h】

Interactions of the the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease

机译:吡啶-2-羧醛异烟酰yl类螯合剂与铁和DNA的相互作用:对铁超负荷疾病治疗毒性的影响

获取原文
获取原文并翻译 | 示例

摘要

Iron chelation therapy for the management of iron-overload disease is dominated by desferrioxamine (DFO). However, treatment using DFO is very arduous. Recently, novel Fe chelators of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone (PCIH) class have shown high chelation efficacy and the potential to replace DFO. A critical consideration in the design of alternatives to DFO is that the chelator forms a redoxinert Fe complex. In the present study, the participation of Fe complexes in redox reactions has been investigated. Ascorbate oxidation in the presence of Fe(III) or benzoate hydroxylation in the presence of Fe(II) was not enhanced by the PCIH analogues. However, redox-induced DNA strand breaks were observed with these ligands under highly oxidizing conditions in the presence of Fe(II) and hydrogen peroxide. Experiments then examined the interactions of the CPIH analogues with DNA, and this was found to be weak. Considering this, we suggest that under extreme conditions seen in the DNA-strand break assay, weak DNA-binding may potentiate the redox activity of the PCIH analogues. However, importantly, in contrast to naked plasmid DNA, DNA damage by these chelators using intact human cells was not significant. Collectively, our results support the potential of the PCIH analogues for the treatment of Fe overload.
机译:铁螯合疗法用于治疗铁超负荷疾病,主要是去铁胺(DFO)。然而,使用DFO的治疗非常艰巨。最近,吡啶-2-羧醛异烟酰yl(PCIH)类的新型铁螯合剂显示出高螯合功效和取代DFO的潜力。 DFO替代品设计中的一个关键考虑因素是,螯合剂会形成氧化还原铁复合物。在本研究中,已经研究了铁络合物参与氧化还原反应。 PCIH类似物不能增强在Fe(III)存在下的抗坏血酸氧化或在Fe(II)存在下的苯甲酸酯羟基化。但是,在Fe(II)和过氧化氢的存在下,在高度氧化条件下,这些配体观察到了氧化还原诱导的DNA链断裂。然后,实验检查了CPIH类似物与DNA的相互作用,发现这种相互作用很弱。考虑到这一点,我们建议在DNA链断裂试验中看到的极端条件下,弱的DNA结合可能会增强PCIH类似物的氧化还原活性。但是,重要的是,与裸露的质粒DNA相比,这些螯合剂使用完整的人类细胞对DNA的破坏并不明显。总的来说,我们的结果支持PCIH类似物在治疗铁超负荷方面的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号